Journey Medical’s Q2 earnings soar with Amrozi leading the charge, raking in $8.1M—up sharply thanks to more doctors prescribing it and better insurance coverage. New sales hires and record prescription numbers (5,300+ in June) signal explosive growth, with over 4,500 dermatologists now on board. Their new anti-itch cream, Urox, is gaining early traction. Total revenue jumped 23% YoY to $18.5M, net loss narrowed, and cash reserves hit $25M—signaling a path to profitability. Next up: expanding payer access, exploring global licensing, and adding new dermatology assets—all pointing to a breakout 2026.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
